The effects of preexisting immunity to influenza on responses to influenza vectors in mice

Vaccine
William A LangleyDavid A Steinhauer

Abstract

The use of viral vectors as vaccine candidates has shown promise against a number of pathogens. However, preexisting immunity to these vectors is a concern that must be addressed when deciding which viruses are suitable for use. A number of properties, including the existence of antigenically distinct subtypes, make influenza viruses attractive candidates for use as viral vectors. Here, we evaluate the ability of influenza viral vectors containing inserts of foreign pathogens to elicit antibody and CD8(+) T cell responses against these foreign antigens in the presence of preexisting immunity to influenza virus in mice. Specifically, responses to an H3N1-based vector expressing a 90 amino acid polypeptide derived from the protective antigen (PA) of Bacillus anthracis or an H1N1-based vector containing a CD8(+) T cell epitope from the glycoprotein (GP) of lymphocytic choriomeningitis virus were evaluated following infections with either homosubtypic or heterosubtypic influenza viruses. We found that mice previously infected with influenza viruses, even those expressing HA and NA proteins of completely different subtypes, were severely compromised in their ability to mount an immune response against the inserted epitopes. This inh...Continue Reading

References

Jan 1, 1987·Annual Review of Biochemistry·D C Wiley, J J Skehel
Jun 1, 1995·Biologicals : Journal of the International Association of Biological Standardization·A García-Sastre, P Palese
Oct 1, 1995·Annals of Internal Medicine·P A GrossR A Levandowski
Feb 12, 1998·The Journal of Experimental Medicine·M B Graham, T J Braciale
Oct 10, 1998·Journal of Virology·J JamesonF A Ennis
Mar 12, 1999·Journal of Virology·A I RamsinghL E Armstrong
Aug 4, 1999·Proceedings of the National Academy of Sciences of the United States of America·G NeumannY Kawaoka
Nov 14, 2002·Annual Review of Genetics·David A Steinhauer, John J Skehel
Dec 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jenni M VuolaAdrian V S Hill
Feb 15, 2005·Journal of Virology·Ron A M FouchierAlbert D M E Osterhaus
Mar 23, 2005·Proceedings of the National Academy of Sciences of the United States of America·Daniel P WebsterAdrian V S Hill
Aug 17, 2005·Journal of Virology·E G M BerkhoffG F Rimmelzwaan
Feb 14, 2006·Immunity·Peter PaleseAdolfo Garcia-Sastre
Feb 24, 2006·Emerging Infectious Diseases·Paul G ThomasPeter C Doherty
Jul 6, 2006·Virology·Mary Ellen SmithMatthias J Schnell
Jan 4, 2007·Proceedings of the National Academy of Sciences of the United States of America·Huynh-Hoa BuiAlessandro Sette
Nov 9, 2007·The New England Journal of Medicine·Ian J AmannaMark K Slifka
Jan 30, 2009·Antiviral Research·Dale L Barnard
May 13, 2009·The Journal of Infectious Diseases·Samira MubarekaPeter Palese
Jul 16, 2009·Protein and Peptide Letters·Karen J CrossDavid A Steinhauer
Oct 21, 2009·Vaccine·Guus F RimmelzwaanAlbert D M E Osterhaus
Dec 8, 2009·Nature Reviews. Microbiology·Simon J Draper, Jonathan L Heeney

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.